Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet
08:30am, Monday, 17'th Nov 2025
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at th
Here's Why Novartis (NVS) is a Strong Value Stock
10:40am, Friday, 14'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis AG $NVS Shares Sold by Arvest Bank Trust Division
04:46am, Friday, 14'th Nov 2025
Arvest Bank Trust Division trimmed its position in Novartis AG (NYSE: NVS) by 71.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Co
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
10:10am, Thursday, 13'th Nov 2025
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Interim Report for the period July - September 2025: BioArctic
02:19am, Thursday, 13'th Nov 2025
STOCKHOLM , Nov. 13, 2025 /PRNewswire/ -- Broadening our portfolio with new projects and partnerships Events during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress f
New, effective anti-malaria drug could help fight rising resistance, says Novartis
05:07pm, Wednesday, 12'th Nov 2025
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial resul
Americana Partners LLC Buys 792 Shares of Novartis AG $NVS
04:04am, Tuesday, 11'th Nov 2025
Americana Partners LLC grew its position in Novartis AG (NYSE: NVS) by 3.1% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,547
Novartis opens new plant in California to make cancer drugs
09:34am, Monday, 10'th Nov 2025
Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. s
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
01:15am, Tuesday, 04'th Nov 2025
Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN
Meharry and Novartis Partner on HEART Initiative for Healthier Communities
08:00am, Monday, 03'rd Nov 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)--The School of Global Health at Meharry Medical College, in partnership with Novartis, today announced the launch of Health Assessments and Rapid Transformation (HEAR
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
04:46pm, Thursday, 30'th Oct 2025
Novartis AG ( NVS ) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Develop
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 29'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials
10:30am, Wednesday, 29'th Oct 2025
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the Americ
3 Investable Laggards In An Overbought Market
05:13pm, Tuesday, 28'th Oct 2025
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
01:41pm, Tuesday, 28'th Oct 2025
Novartis AG (NYSE:NVS ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirs
